Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frankfurt (oder)

61 clinical trials in Frankfurt (oder), Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt (oder) at a glance
61
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Frankfurt (oder)

Open in trial search

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fruquintinib
  • Sponsor:Fondation Franc.Cancerologie Digestive

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frankfurt (oder)

What the registry says about research in the country

01 Hemic and Lymphatic Diseases

Clinical research in Frankfurt (oder) is strongly focused on blood cancers, with studies covering follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and multiple myeloma. These trials are mainly testing new treatment combinations and comparing them with current standard care to improve response and disease control.

  • New approaches for follicular lymphoma and related indolent lymphomas
  • Treatment studies in relapsed or refractory lymphoma and B-cell non-Hodgkin’s lymphoma
  • Therapy comparisons for chronic lymphocytic leukemia in patients with other health conditions
  • Trials in multiple myeloma and other hematologic cancers

The overall goal is to find safer and more effective options for patients with complex hematologic malignancies, especially where long-term disease control is a priority.

02 Neoplasms

Another major area of trial activity is cancer research in broader tumor types, including diffuse large B-cell lymphoma and other aggressive lymphomas. These studies are evaluating whether newer targeted or combined therapies can improve outcomes for older adults and people who may not tolerate intensive treatment well.

  • Studies for diffuse large B-cell lymphoma and other aggressive B-cell lymphomas
  • Research in older or less fit patients needing gentler treatment options
  • Comparisons of new immunotherapy-based regimens with standard chemotherapy
  • Trials designed to improve remission rates and disease-free survival

This reflects a practical effort to refine treatment choices in oncology, with attention to both effectiveness and tolerability.

03 Nervous System Diseases

Clinical trials in nervous system disease are centered on Alzheimer’s disease, exploring whether an investigational therapy can be safe and well tolerated while also influencing disease-related brain changes. The research aims to support earlier intervention and improve understanding of how treatment may affect the course of memory and cognitive decline.

  • Studies in Alzheimer’s disease at risk and early symptom stages
  • Research on safety and tolerability of a potential new therapy
  • Evaluation of effects on brain amyloid accumulation
  • Work aimed at better treatment strategies for neurodegenerative disease

These trials contribute to efforts in neurology to slow progression and improve future care for people affected by cognitive disorders.

04 Mixed Hematologic and Oncology Research

Several studies in the city also bridge multiple areas of hematology and oncology, including treatment strategies for patients preparing for allogeneic stem cell transplantation. These trials are looking at whether alternative regimens can better control disease before transplant and improve outcomes afterward.

  • Research in higher-risk MDS and oligoblastic AML
  • Treatment planning before allogeneic blood cell transplantation
  • Studies comparing disease control strategies ahead of transplant
  • Focus on improving progression-free and event-free survival

The research supports more tailored treatment pathways for patients with challenging blood disorders and advanced cancer-related conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.